NCT07667673Active, not recruiting
Multimodality RV Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 PAH
Multimodality Imaging-Based Right Ventricular Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 Pulmonary Arterial Hypertension: The MIRROR-PAH Study
Source: ClinicalTrials.gov · Last updated 18 Sept 2026
Brief summary (registry, in English)
The MIRROR-PAH is a single-center, prospective, observational cohort study evaluating the incremental value of multimodality imaging-derived right ventricular characteristics for risk stratification in patients with Group 1 pulmonary arterial hypertension (PAH). The study aims to determine whether incorporation of echocardiographic and cardiac magnetic resonance (CMR)-derived right ventricular parameters into established non-invasive risk assessment models results in risk reclassification and improves identification of patients at risk for short-term clinical worsening. Adult patients with established Group 1 PAH undergoing routine follow-up and with available right heart catheterization (RHC) and CMR data will be consecutively enrolled. Clinical, laboratory, echocardiographic, and follow-up data will be prospectively collected over a 6-month period. Associations between multimodality imaging findings, invasive hemodynamic measurements, risk classification, and short-term clinical outcomes will be evaluated.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 6 Jun 2026
- Start date
- 11 May 2026
- Primary completion date
- 28 Feb 2027
- Lead sponsor
- Istanbul University - Cerrahpasa
- NCT number
- NCT07667673
What you commit to
- Study type: Observational
- Planned participants: 50
- From 11 May 2026 to the primary completion date, 28 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Pulmonary hypertension groups other than Group 1 PAH (Groups 2-5 PH)
- Absence of either right heart catheterization or cardiac magnetic resonance imaging data within a clinically relevant time interval
Age
- Age younger than 18 years
Other
- Incomplete clinical or imaging data preventing analysis
- Unavailable follow-up data
Who the study is looking for
- Adults aged 18 years or older
- Diagnosis of Group 1 pulmonary arterial hypertension (PAH) according to ESC/ERS guidelines
- Followed at the study center with a diagnosis of PAH
- Availability of right heart catheterization (RHC) and cardiac magnetic resonance (CMR) imaging data obtained within a clinically relevant time interval
- Availability of analyzable clinical, imaging, and hemodynamic data
- Willingness to participate in the study and provision of written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istanbul University Cerrahpaşa Institute of Cardiology Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.